We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aurora Cannabis Inc. (ACB) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Aurora Cannabis Inc. (ACB - Free Report) closed at $2.07 in the latest trading session, marking a +1.47% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.11%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq added 0.2%.
Heading into today, shares of the company had gained 2.51% over the past month, outpacing the Medical sector's gain of 0.94% and lagging the S&P 500's gain of 3.25% in that time.
Wall Street will be looking for positivity from ACB as it approaches its next earnings report date. The company is expected to report EPS of -$0.04, unchanged from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $62.22 million, up 51.76% from the year-ago period.
ACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.14 per share and revenue of $293.91 million. These results would represent year-over-year changes of +36.36% and +48.39%, respectively.
Investors should also note any recent changes to analyst estimates for ACB. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 6.81% lower. ACB is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aurora Cannabis Inc. (ACB) Outpaces Stock Market Gains: What You Should Know
Aurora Cannabis Inc. (ACB - Free Report) closed at $2.07 in the latest trading session, marking a +1.47% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.11%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq added 0.2%.
Heading into today, shares of the company had gained 2.51% over the past month, outpacing the Medical sector's gain of 0.94% and lagging the S&P 500's gain of 3.25% in that time.
Wall Street will be looking for positivity from ACB as it approaches its next earnings report date. The company is expected to report EPS of -$0.04, unchanged from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $62.22 million, up 51.76% from the year-ago period.
ACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.14 per share and revenue of $293.91 million. These results would represent year-over-year changes of +36.36% and +48.39%, respectively.
Investors should also note any recent changes to analyst estimates for ACB. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 6.81% lower. ACB is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.